HER2Know
HER2Know Logo
  • IHC Atlas
  • Supporting Resources
  • IHC Knowledge Check

SUPPORTING RESOURCES

Peer-developed
educational materials


Here you will find a broad range of educational resources to support your HER2 IHC scoring consistency and best practice recommendations from the Pathology Faculty. View the materials, including The significance of HER2 documentary, below.

  1. HER2
  2. Clinical practice support
  3. Clinical practice guidelines

Close Filters Add Filters

Sort by:
Newest to Oldest
  • Newest to Oldest
Filters:
Results

Search Results

View more

ANIMATION

Identifying Low Levels of HER2 Expression in Breast Cancer

Short animation which describes CAP’s 2023 updated reporting template for HER2-low breast cancer and best practices for pathologists when reviewing these cases. (1.5 mins)

Play video

ANIMATION

Recognizing HER2 staining patterns at the low end of the spectrum

A short animation, discussing best practice recommendations for scoring HER2 by IHC with Dr. Feldman. (4 mins)

Play video

DOCUMENTARY

The significance of HER2

Dr. Marilyn Bui, pathologist, and Dr. Hope S. Rugo, oncologist, discuss the evolution of HER2 as a breast cancer biomarker in this mini documentary-style film. (19 mins)

Play video

ANIMATION

Lives behind slides

This short animation depicts patients with breast cancer, whose lives are impacted by their HER2 status. (2 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Slide validation

Dr. Bui discusses specimen requirements and recommendations to reduce pre-analytical variables. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Approaching the scoring

Dr. Tozbikian demonstrates current approaches to HER2 IHC scoring. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Areas of diagnostic pitfalls

Dr. Hicks highlights considerations when interpreting HER2 status. (19 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Correlating interpretation with clinical history

Dr. Feldman discusses histopathologic findings in view of the clinical background. (15 mins)

Play video

E-LEARNING

From past to present: The significance of HER2 in breast cancer

In the first session of this three-part program, Dr. Wei explores the spectrum of HER2 expression with slide reviews from Dr. Krishnamurthy and Dr. Wen. (48 mins)

Play video

E-LEARNING

Consistency with practice: Standardizing the approach to HER2 IHC scoring

Dr. Hicks discusses the importance of pre-analytic, analytic, and post-analytic variables. Dr. Khoury and Dr. Tozbikian review artifacts and indeterminate staining patterns. (57 mins) 

Play video

E-LEARNING

Challenge accepted: Best practices for scoring HER2 across the spectrum

Dr. Jaffer provides guidance on recognition of HER2 staining patterns and heterogeneity. Dr. Krishnamurthy and Dr. Bui present challenging HER2 IHC cases. (60 mins)

Play video

E-LEARNING

Interpreting HER2 in breast cancer: USCAP course summary

Summary documents of the USCAP e-learning program Interpreting HER2 in breast cancer: A full spectrum of possibilities.

Download

DOCUMENTARY

The significance of HER2: Trailer

A short preview of a mini documentary-style film presented by Dr. Marilyn Bui and Dr. Hope S. Rugo. (2 mins)

Play video

E-LEARNING

Topic 1: Clinical innovation across the HER2 pathway

Dr. Krishnamurthy presents the evolution of HER2 in clinical practice. (7 mins)

Play video

E-LEARNING

Topic 2: The spectrum of HER2 expression

Dr. Tozbikian reviews current HER2 guidelines and the significance of discrete HER2 IHC scoring. (9 mins)

Play video

E-LEARNING

Topic 3: Overcoming challenges in assessing HER2 expression across the spectrum

Dr. Hicks highlights best clinical practices for differentiating low levels of HER2. (11 mins)

Play video

ANIMATION

Identifying Low Levels of HER2 Expression in Breast Cancer

Short animation which describes CAP’s 2023 updated reporting template for HER2-low breast cancer and best practices for pathologists when reviewing these cases. (1.5 mins)

Play video

ANIMATION

Recognizing HER2 staining patterns at the low end of the spectrum

A short animation, discussing best practice recommendations for scoring HER2 by IHC with Dr. Feldman. (4 mins)

Play video

DOCUMENTARY

The significance of HER2

Dr. Marilyn Bui, pathologist, and Dr. Hope S. Rugo, oncologist, discuss the evolution of HER2 as a breast cancer biomarker in this mini documentary-style film. (19 mins)

Play video

ANIMATION

Lives behind slides

This short animation depicts patients with breast cancer, whose lives are impacted by their HER2 status. (2 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Slide validation

Dr. Bui discusses specimen requirements and recommendations to reduce pre-analytical variables. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Approaching the scoring

Dr. Tozbikian demonstrates current approaches to HER2 IHC scoring. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Areas of diagnostic pitfalls

Dr. Hicks highlights considerations when interpreting HER2 status. (19 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Correlating interpretation with clinical history

Dr. Feldman discusses histopathologic findings in view of the clinical background. (15 mins)

Play video

E-LEARNING

From past to present: The significance of HER2 in breast cancer

In the first session of this three-part program, Dr. Wei explores the spectrum of HER2 expression with slide reviews from Dr. Krishnamurthy and Dr. Wen. (48 mins)

Play video

E-LEARNING

Consistency with practice: Standardizing the approach to HER2 IHC scoring

Dr. Hicks discusses the importance of pre-analytic, analytic, and post-analytic variables. Dr. Khoury and Dr. Tozbikian review artifacts and indeterminate staining patterns. (57 mins) 

Play video

E-LEARNING

Challenge accepted: Best practices for scoring HER2 across the spectrum

Dr. Jaffer provides guidance on recognition of HER2 staining patterns and heterogeneity. Dr. Krishnamurthy and Dr. Bui present challenging HER2 IHC cases. (60 mins)

Play video

E-LEARNING

Interpreting HER2 in breast cancer: USCAP course summary

Summary documents of the USCAP e-learning program Interpreting HER2 in breast cancer: A full spectrum of possibilities.

Download

DOCUMENTARY

The significance of HER2: Trailer

A short preview of a mini documentary-style film presented by Dr. Marilyn Bui and Dr. Hope S. Rugo. (2 mins)

Play video

E-LEARNING

Topic 1: Clinical innovation across the HER2 pathway

Dr. Krishnamurthy presents the evolution of HER2 in clinical practice. (7 mins)

Play video

E-LEARNING

Topic 2: The spectrum of HER2 expression

Dr. Tozbikian reviews current HER2 guidelines and the significance of discrete HER2 IHC scoring. (9 mins)

Play video

E-LEARNING

Topic 3: Overcoming challenges in assessing HER2 expression across the spectrum

Dr. Hicks highlights best clinical practices for differentiating low levels of HER2. (11 mins)

Play video
  1. Teaser 17
  2. Teaser 12
  3. Teaser 10
  4. Teaser 11
  5. Teaser 1
  6. Teaser 2
  7. Teaser 3
  8. Teaser 4
  9. Teaser 5
  10. Teaser 6
  11. Teaser 7
  12. Teaser 8
  13. Teaser 9
  14. Teaser 13
  15. Teaser 14
  16. Teaser 15
  1. Teaser 17
  2. Teaser 12
  3. Teaser 10
  4. Teaser 11
  5. Teaser 1
  6. Teaser 2
  7. Teaser 3
  8. Teaser 4
  9. Teaser 5
  10. Teaser 6
  11. Teaser 7
  12. Teaser 8
  13. Teaser 9
  14. Teaser 13
  15. Teaser 14
  16. Teaser 15

MICROSCOPY SERIES

Microscopy review:
Slide validation

Dr. Bui discusses specimen requirements and recommendations to reduce pre-analytical variables. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Approaching the scoring

Dr. Tozbikian demonstrates current approaches to HER2 IHC scoring. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Areas of diagnostic pitfalls

Dr. Hicks highlights considerations when interpreting HER2 status. (19 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Correlating interpretation with clinical history

Dr. Feldman discusses histopathologic findings in view of the clinical background. (15 mins)

Play video

E-LEARNING

From past to present: The significance of HER2 in breast cancer

In the first session of this three-part program, Dr. Wei explores the spectrum of HER2 expression with slide reviews from Dr. Krishnamurthy and Dr. Wen. (48 mins)

Play video

E-LEARNING

Consistency with practice: Standardizing the approach to HER2 IHC scoring

Dr. Hicks discusses the importance of pre-analytic, analytic, and post-analytic variables. Dr. Khoury and Dr. Tozbikian review artifacts and indeterminate staining patterns. (57 mins) 

Play video

E-LEARNING

Challenge accepted: Best practices for scoring HER2 across the spectrum

Dr. Jaffer provides guidance on recognition of HER2 staining patterns and heterogeneity. Dr. Krishnamurthy and Dr. Bui present challenging HER2 IHC cases. (60 mins)

Play video

E-LEARNING

Interpreting HER2 in breast cancer: USCAP course summary

Summary documents of the USCAP e-learning program Interpreting HER2 in breast cancer: A full spectrum of possibilities.

Download

ALGORITHM

Algorithmic approach to standardizing HER2 scoring

Dr. Hicks shares his approach for scoring HER2 by IHC.

Download

GUIDE

HER2 IHC scoring resource and guide

A summarized approach to HER2 IHC interpretation, based on most recent guidelines and expert opinion.

Download

GUIDE

HER2 differentiation in practice: a quick visual guide

An in-lab visual reference for recognizing HER2 IHC staining patterns to assist clinical practice.

Download

GUIDE

HER2 expression in breast cancer: A comprehensive reference

A downloadable comprehensive guide to HER2 IHC scoring.

Download

ANIMATION

Recognizing HER2 staining patterns at the low end of the spectrum

A short animation, discussing best practice recommendations for scoring HER2 by IHC with Dr. Feldman. (4 mins)

Play video

ANIMATION

Identifying Low Levels of HER2 Expression in Breast Cancer

Short animation which describes CAP’s 2023 updated reporting template for HER2-low breast cancer and best practices for pathologists when reviewing these cases. (1.5 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Slide validation

Dr. Bui discusses specimen requirements and recommendations to reduce pre-analytical variables. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review:
Approaching the scoring

Dr. Tozbikian demonstrates current approaches to HER2 IHC scoring. (17 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Areas of diagnostic pitfalls

Dr. Hicks highlights considerations when interpreting HER2 status. (19 mins)

Play video

MICROSCOPY SERIES

Microscopy review: Correlating interpretation with clinical history

Dr. Feldman discusses histopathologic findings in view of the clinical background. (15 mins)

Play video

E-LEARNING

From past to present: The significance of HER2 in breast cancer

In the first session of this three-part program, Dr. Wei explores the spectrum of HER2 expression with slide reviews from Dr. Krishnamurthy and Dr. Wen. (48 mins)

Play video

E-LEARNING

Consistency with practice: Standardizing the approach to HER2 IHC scoring

Dr. Hicks discusses the importance of pre-analytic, analytic, and post-analytic variables. Dr. Khoury and Dr. Tozbikian review artifacts and indeterminate staining patterns. (57 mins) 

Play video

E-LEARNING

Challenge accepted: Best practices for scoring HER2 across the spectrum

Dr. Jaffer provides guidance on recognition of HER2 staining patterns and heterogeneity. Dr. Krishnamurthy and Dr. Bui present challenging HER2 IHC cases. (60 mins)

Play video

E-LEARNING

Interpreting HER2 in breast cancer: USCAP course summary

Summary documents of the USCAP e-learning program Interpreting HER2 in breast cancer: A full spectrum of possibilities.

Download

ALGORITHM

Algorithmic approach to standardizing HER2 scoring

Dr. Hicks shares his approach for scoring HER2 by IHC.

Download

GUIDE

HER2 IHC scoring resource and guide

A summarized approach to HER2 IHC interpretation, based on most recent guidelines and expert opinion.

Download

GUIDE

HER2 differentiation in practice: a quick visual guide

An in-lab visual reference for recognizing HER2 IHC staining patterns to assist clinical practice.

Download

GUIDE

HER2 expression in breast cancer: A comprehensive reference

A downloadable comprehensive guide to HER2 IHC scoring.

Download

ANIMATION

Recognizing HER2 staining patterns at the low end of the spectrum

A short animation, discussing best practice recommendations for scoring HER2 by IHC with Dr. Feldman. (4 mins)

Play video

ANIMATION

Identifying Low Levels of HER2 Expression in Breast Cancer

Short animation which describes CAP’s 2023 updated reporting template for HER2-low breast cancer and best practices for pathologists when reviewing these cases. (1.5 mins)

Play video
  1. Teaser 1
  2. Teaser 2
  3. Teaser 3
  4. Teaser 4
  5. Teaser 5
  6. Teaser 6
  7. Teaser 7
  8. Teaser 8
  9. Teaser 10
  10. Teaser 11
  11. Teaser 12
  12. Teaser 13
  13. Teaser 9
  14. Teaser 17
  1. Teaser 1
  2. Teaser 2
  3. Teaser 3
  4. Teaser 4
  5. Teaser 5
  6. Teaser 6
  7. Teaser 7
  8. Teaser 8
  9. Teaser 10
  10. Teaser 11
  11. Teaser 12
  12. Teaser 13
  13. Teaser 9
  14. Teaser 17

Close Filters Add Filters

Sort by:
Newest to Oldest
  • Newest to Oldest
Filters:
Results

Search Results

View more

GUIDELINES

CAP quantitative image analysis (QIA) guidelines

Recommendations for optimizing interpretation of HER2 IHC performed by QIA in breast cancer.

View guidelines

GUIDELINES

ASCO-CAP HER2 testing guidelines

Recommendations for improving accuracy and standardization of HER2 testing in breast cancer. In 2023, ASCO-CAP published a guideline update, which affirmed the guidelines provided here.1

View guidelines

GUIDELINES

CAP quantitative image analysis (QIA) guidelines

Recommendations for optimizing interpretation of HER2 IHC performed by QIA in breast cancer.

View guidelines

GUIDELINES

ASCO-CAP HER2 testing guidelines

Recommendations for improving accuracy and standardization of HER2 testing in breast cancer. In 2023, ASCO-CAP published a guideline update, which affirmed the guidelines provided here.1

View guidelines
  1. Teaser2
  2. Teaser1
  1. Teaser2
  2. Teaser1

Close Filters Add Filters

Sort by:
Newest to Oldest
  • Newest to Oldest
Filters:
Results

Search Results

View more

CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; USCAP, United States and Canadian Academy of Pathology.

1. Wolff AC, et al. Arch Pathol Lab Med 2023. https://doi.org/10.5858/arpa.2023-0950-SA.

HER2Know Logo

Request an AstraZeneca Medical Affairs Representative Follow-Up

Identifying Low Levels of HER2 Expression in Breast Cancer

Short animation which describes CAP’s 2023 updated reporting template for HER2-low breast cancer and best practices for pathologists when reviewing these cases. (1.5 mins)

Her2know Logo

Quick links

  • IHC Atlas
  • Supporting Resources
  • IHC Knowledge Check

About us

  • Contact Us
  • Request Medical Follow-Up
  • AstraZeneca
  • AZ Medical
  • Daiichi Sankyo Company
  • DSI Medical

Legal

  • Privacy Notice
  • Cookie Policy
  • Legal Notices and Terms of Uses
Daiichi Logo

©2023 Daiichi Sankyo, Inc. and AstraZeneca
US-77216, PP-US-8201a-1686 10/23

Microscopy review: Slide validation

Dr. Bui discusses specimen requirements and recommendations to reduce pre-analytical variables. (17 mins) 

Microscopy review: Approaching the scoring

Dr. Tozbikian demonstrates current approaches to HER2 IHC scoring. (17 mins)

Microscopy review: Areas of diagnostic pitfalls

Dr. Hicks highlights considerations when interpreting HER2 status. (19 mins)

Microscopy review: Correlating interpretation with clinical history 

Dr. Feldman discusses histopathologic findings in view of the clinical background. (15 mins)

From past to present: The significance of HER2 in breast cancer

Dr. Jaffer provides guidance on recognition of HER2 staining patterns and heterogeneity. Dr. Krishnamurthy and Dr. Bui present challenging HER2 IHC cases. (60 mins)

Consistency with practice: Standardizing the approach to HER2 IHC scoring

Dr. Hicks discusses the importance of pre-analytic, analytic, and post-analytic variables. Dr. Khoury and Dr. Tozbikian review artifacts and indeterminate staining patterns. (57 mins)

Challenge accepted: Best practices for scoring HER2 across the spectrum

Dr. Jaffer provides guidance on recognition of HER2 staining patterns and heterogeneity. Dr. Krishnamurthy and Dr. Bui present challenging HER2 IHC cases. (60 mins)

The significance of HER2: Trailer

A short preview of a mini documentary-style film presented by Dr. Marilyn Bui and Dr. Hope S. Rugo. (2 mins)

The significance of HER2

Dr. Marilyn Bui, pathologist, and Dr. Hope S. Rugo, oncologist, discuss the evolution of HER2 as a breast cancer biomarker in this mini documentary-style film. (19 mins)

Lives behind slides

This short animation depicts patients with breast cancer, whose lives are impacted by their HER2 status. (2 mins)

Recognizing HER2 staining patterns at the low end of the spectrum

A short animation, discussing best practice recommendations for scoring HER2 by IHC with Dr. Feldman. (4 mins)

Topic 1: Clinical innovation across the HER2 pathway

Dr. Krishnamurthy presents the evolution of HER2 in clinical practice. (7 mins)

Topic 2: The spectrum of HER2 expression

Dr. Tozbikian reviews current HER2 guidelines and the significance of discrete HER2 IHC scoring. (9 mins)

Topic 3: Overcoming challenges in assessing HER2 expression across the spectrum

Dr. Hicks highlights best clinical practices for differentiating low levels of HER2. (11 mins)

Microscopy review: Slide validation

Dr. Bui discusses specimen requirements and recommendations to reduce pre-analytical variables. (17 mins) 

Welcome to HER2Know

This website is intended to help healthcare professionals practicing in the U.S. find and access scientifically balanced, evidence-based, and peer-led information and professional resources in support of HER2 IHC evaluation in breast cancer.

The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This information is provided for educational purposes only. It is not intended for use in the diagnosis or treatment of individual patients.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca or Daiichi Sankyo Company authorized person

What is an AstraZeneca or Daiichi Sankyo Company authorized person?

This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca or Daiichi Sankyo Company person. US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. This website is not intended for use by US Field Sales personnel. None of the content of this site should be directly linked or distributed without approval.

Self Certification Buttons
No, take me to AstraZeneca.com Self Certification Buttons